On 5 July 2024 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation No. 57/2024 on the evaluation of the drug Nucala (mepolizumab) as part of the drug program “Treatment of patients with sinusitis with nasal polyps (ICD-10: J32, J33)”